Ninth Circuit ruling extends antitrust protection
This article was originally published in The Gray Sheet
Executive Summary
In a Jan. 6 decision on Allied Orthopedic Appliances Inc. v. Tyco Health Care Group LP, the Ninth Circuit held that U.S. antitrust laws do not prevent a monopolist from improving its products, even when the improvement adversely affects competition, according to a client advisory from the law firm Arnold & Porter. Plaintiffs had alleged that a redesign of a medical device composed of a sensor and a monitor to receive, interpret and display information from the sensor rendered the device's monitors incompatible with the competitors' generic sensors, according to the advisory. However, the court ruled in favor of the defendant, who proved that the redesign also provided new features and reduced the overall cost, the law firm notes. Arnold & Porter cautions that while manufacturers now have more antitrust protection in the Ninth Circuit, other state, federal and foreign jurisdictions may have laws "that are less clear than, or even contrary to, Allied.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.